Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Suresh Didwania

Internal Medicine Kankakee, IL Medical Doctor

NPI 1093777880 CMS profile 322358

555 W Court St, Suite 400, Kankakee, IL 60901

Open in the dashboard

General payments

$8,873

546 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Suresh Didwania of Kankakee, IL is reported in the CMS Open Payments database as having received $8,873 across 546 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 93rd percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $275 9
2024 General $1,314 70
2023 General $1,473 80
2022 General $1,632 103
2021 General $1,386 82
2020 General $1,194 80
2019 General $1,601 122

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Suresh Didwania
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Suresh Didwania were reported at $275. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Suresh Didwania Internal Medicine median Middle half National median
2019 $1,601 $159 $48–$570 $163
2020 $1,194 $119 $33–$402 $114
2021 $1,386 $135 $37–$521 $132
2022 $1,632 $141 $42–$496 $149
2023 $1,473 $149 $45–$519 $160
2024 $1,314 $154 $47–$537 $164
2025 $275 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novo Nordisk Inc $831 56 payments
  2. AstraZeneca Pharmaceuticals LP $776 46 payments
  3. Boehringer Ingelheim Pharmaceuticals, Inc. $647 32 payments
  4. Janssen Pharmaceuticals, Inc $575 38 payments
  5. Sanofi-Aventis U.S. LLC $466 31 payments
  6. Merck Sharp & Dohme Corporation $458 29 payments
  7. AbbVie, Inc. $406 24 payments
  8. Bayer HealthCare Pharmaceuticals Inc. $370 17 payments
  9. GlaxoSmithKline, LLC. $364 21 payments
  10. Lilly USA, LLC $354 22 payments
  11. Other $3,627 230 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $8,579 539 payments
  2. Education $294 7 payments
Products named General payments · program years 2019–2025
  1. Ozempic $711 47 payments
  2. XARELTO $575 38 payments
  3. JARDIANCE $514 24 payments
  4. GEMTESA $438 26 payments
  5. FARXIGA $428 23 payments
  6. Kerendia $370 17 payments
  7. RYBELSUS $320 21 payments
  8. LINZESS $304 22 payments
  9. STEGLATRO $285 18 payments
  10. VIBERZI $280 21 payments
  11. Other $8,272 526 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 240 drugs

Part D claims

23,005

Median for Internal Medicine: 777

Drug cost

$2,026,430

Median for Internal Medicine: $73,373

Branded share of claims

23.7%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 480 $184,747
Austedo Xr Deutetrabenazine Brand 23 $175,700
Januvia Sitagliptin Phosphate Brand 158 $142,401
Ozempic Semaglutide Brand 101 $121,124
Tradjenta Linagliptin Brand 145 $100,694
Austedo Deutetrabenazine Brand 38 $96,223
Jardiance Empagliflozin Brand 129 $91,037
Entresto Sacubitril/Valsartan Brand 107 $87,459
Farxiga Dapagliflozin Propanediol Brand 90 $69,258
Linzess Linaclotide Brand 112 $52,309

The 10 drugs with the highest cost, of 240 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 34 billing codes

Paid by Medicare

$259,169

Of which drugs: $6,825

Medicare patients

521

Average age 74

Services billed

4,190

272 women, 249 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 48%
Ischemic heart disease 42%
Diabetes 41%
Chronic kidney disease 40%
Depression 38%
Heart failure 36%
Atrial fibrillation 29%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Pcv20 vaccine im 90677 Office 17 17 $4,901
Vaccine for influenza for injection into muscle 90662 Office 23 23 $1,852

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 31 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Ozempic
  • Novo Nordisk Inc $153
$153 101 —
FARXIGA
  • AstraZeneca Pharmaceuticals LP $95
$95 90 —
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $67
  • Lilly USA, LLC $27
$94 129 —
VOQUEZNA
  • Phathom Pharmaceuticals, Inc. $83
$83 — —
LOKELMA
  • AstraZeneca Pharmaceuticals LP $73
$73 11 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 31 with Patron

Records

546 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record